华平信息技术股份有限公司 公告 证券代码：300074 证券简称：华平股份 编号：202507-034 应公司经营发展需求，公司对经营范围进行了新增，新增内容为第二类增值 电信业务，另公司根据工商登记注册对经营范围表述规范的具体要求对公司经营 范围的表述进行了修改，具体情况如下： | 修订前 | 修订后 | | --- | --- | | 公司经营范围是：计算机软硬件及其他电子产品的 | 公司的经营范围：专业设计服务、电子产品销售， | | 设计、销售，计算机系统集成服务，并提供相关的 | 信息系统集成服务、技术服务、技术开发、技术咨 | | 技术服务、技术咨询、技术开发、技术转让，企业 | 询、技术交流、技术转让、技术推广，企业管理咨 | | 管理咨询，社会经济咨询，安全监视报警器材的设 | 询，社会经济咨询服务，安全技术防范系统设计施 | | 计、安装，从事货物及技术的进出口业务，医疗器 | 工服务、安全系统监控服务，货物进出口、技术进 | | 械经营，营养健康咨询服务，电信业务，建筑装修 | 出口 ，第三类医疗器械经营，健康咨询服务（不 | | 装饰工程专业施工。停车场服务，汽车新车销售、 | 含诊疗服 ...

华平信息技术股份有限公司 关于召开2025年第二次临时股东会的通知 本公司及其董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 根据《公司法》和《公司章程》的有关规定，经华平信息技术股份有限公司 （以下简称"公司"）第六届董事会第二次（临时）会议审议通过《关于召开2025 年第二次临时股东会的议案》，现决定于2025年8月19日召开2025年第二次临时股 东会，会议有关事项通知如下： 一、本次股东会召开的基本情况 1、股东会届次：2025年第二次临时股东会。 华平信息技术股份有限公司 2025 年第二次临时股东会 证券代码：300074 证券简称：华平股份 编号：202507-036 2、会议召集人：公司董事会。 3、会议召开的合法性及合规性：经本公司第六届董事会第二次（临时）会 议审议通过《关于召开2025年第二次临时股东会的议案》，现决定于2025年8月19 日召开2025年第二次临时股东会，召集程序符合有关法律、行政法规、部门规章、 规范性文件和《公司章程》的规定。 4、会议召开时间： 现场会议召开时间：2025年8月19日14:30 网络投票日期和时间：2025 ...

华平信息技术股份有限公司 公告 证券代码：300074 证券简称：华平股份 公告编号：202507-033 华平信息技术股份有限公司 第六届监事会第二次（临时）会议决议公告 本公司及其监事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 华平信息技术股份有限公司（下称"公司"）第六届监事会第二次（临时）会 议于2025年7月31日16:00在上海市杨浦区国权北路1688号湾谷科技园A6栋12层会议 室以现场与通讯方式召开。本次会议应参加监事3人，实际出席监事3人。公司董事 会秘书列席了此次会议。公司于2025年7月25日通过邮件等方式通知全体监事，并将 相关提案及内容发送至各与会人员。本次监事会会议的召集、召开符合《中华人民 共和国公司法》和《公司章程》的有关规定。会议由监事会主席邓伟先生主持，与 会监事认真审议，形成如下决议： 一、审议通过《关于2022年股票期权激励计划首次授予第一个行权期届满暨注 销未行权股票期权的议案》 监事会认为：2022年股票期权激励计划首次授予第一个行权期已于2025年5月9 日届满，已授予尚未行权的2.87万份期权由公司注销，符合《上市公司股权激励 ...

华平信息技术股份有限公司 公告 证券代码：300074 证券简称：华平股份 编号：202507-032 华平信息技术股份有限公司 第六届董事会第二次（临时）会议决议公告 本公司及其董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 华平信息技术股份有限公司（下称"公司"）第六届董事会第二次（临时） 会议于 2025 年 7 月 31 日 14:30 在上海市杨浦区国权北路 1688 号湾谷科技园 A6 栋公司会议室以现场方式和通讯方式召开。本次会议应参加董事 9 人，实际出席 董事 9 人，公司全体监事、高级管理人员列席了此次会议。本次董事会通知已于 2025 年 7 月 25 日通过邮件发送至全体董事、监事。本次董事会会议的召集、召 开符合《公司法》和《公司章程》的有关规定。此次会议由董事长蒋孟衡先生主 持，与会董事认真审议，形成如下决议： 一、审议通过《关于增加公司经营范围及修订<公司章程>的议案》 为全面贯彻落实最新法律法规和监管规定要求，进一步规范公司运作机制， 持续提升公司治理水平，根据《公司法》《上市公司章程指引》《深圳证券交易 所创业板股票上市规则》《深圳证券交易 ...

Core Insights - The Internet of Things (IoT) is transitioning from concept to a central industry component, with Shenzhen positioning itself as a "speed pioneer city" in this domain [2][5] - Leading companies in Longgang are leveraging technology to reshape the IoT ecosystem, contributing to the global digital wave [2][5] Group 1: Company Innovations - Shenzhen Macro Electric Technology Co., Ltd. has developed proprietary E-Link and A-Link protocols to efficiently manage data from various sensors, aiding municipal monitoring [3] - Huaping Information Technology Co., Ltd. focuses on visual communication and image intelligence, creating a "smart property management platform" that visualizes operational dynamics [3] - Shenzhen Today International Logistics Technology Co., Ltd. has an industrial IoT platform that connects thousands of devices, supporting automated warehouse management for major factories [3] Group 2: Practical Applications - Macro Electric provides customized solutions across various sectors, including water management and emergency response systems, showcasing its ability to create reusable digital components [4] - Huaping's technology has been instrumental in disaster response, integrating drone footage and monitoring data to create precise situational maps [4] - Today International's platform supports intelligent logistics, having implemented over a thousand projects across various industries [4] Group 3: Future Outlook - The IoT is seen as the third wave of the information industry, with significant potential to enhance efficiency in agriculture and manufacturing [5] - Shenzhen is home to over 70% of China's IoT industry chain, with Longgang aiming to become a new high ground for IoT applications [5] - The "Shenzhen Longgang District Action Plan for Creating an AI Application Demonstration Zone (2024-2025)" encourages the adoption of IoT technologies to accelerate innovation [5]

华平信息技术股份有限公司 公告 证券代码：300074 证券简称：华平股份 公告编号：202505-031 华平信息技术股份有限公司 2024 年年度股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会无增加、变更提案的情况； 2、本次股东会共审议7项议案，该7项议案均获得股东会审议通过； 3、本次股东会以现场投票和网络投票相结合的方式召开； 4、本次股东会没有涉及变更以往股东会已通过的决议。 一、会议召开情况 华平信息技术股份有限公司（以下简称"公司"）2024年年度股东会采取现 场投票和网络投票相结合的方式召开，其中现场会议召开时间为2025年5月23日 14:30，召开地点为上海市杨浦区国权北路1688号湾谷科技园A6栋会议室；通过 深圳证券交易所交易系统进行网络投票的具体时间为2025年5月23日上午 9:15-9:25，9:30-11:30和下午13:00-15:00；通过深圳证券交易所互联网系统投 票的具体时间为2025年5月23日9:15至15:00的任意时间。 本次会议由公司董事会召集，公司董事长蒋孟衡先生 ...

德恒上海律师事务所 关于 华平信息技术股份有限公司 2024年年度股东会之 见证法律意见书 中国上海市虹口区东大名路 501 号上海白玉兰广场办公楼 23 层 200080 Floor23，Sinar Mas Plaza，No.501EastDaMingRoad，Shanghai 电话（Tel）：86-21-55989888 传真（Fax）：86-21-55989898 网址（Website）：www.dehenglaw.com 德恒上海律师事务所 德恒上海律师事务所（以下简称"本所"）接受华平信息技术股份有限公司 （以下简称"公司"）的委托，指派本所承办律师列席公司于 2025 年 5 月 23 日 下午14:30在上海市杨浦区国权北路1688号湾谷科技园A6栋会议室召开的2024 年年度股东会（以下简称"本次股东会"），就本次股东会的召集、召开程序、 现场出席会议人员资格、表决程序等相关事项进行见证，并出具本法律意见。 本所承办律师依据本法律意见出具日前已经发生或存在的事实和《中华人民 共和国证券法》（以下简称"《证券法》"）、《中华人民共和国公司法》（以 下简称"《公司法》"）、《上市公司股东会规则》（ ...

Group 1 - The DRG/DIP concept declined by 3.30%, ranking among the top declines in the concept sector, with notable declines in companies such as Chuangying Huikang, ST Yilianzhong, and Jiahe Meikang [1][2] - The DRG/DIP concept experienced a net outflow of 4.92 billion yuan in main funds, with 19 stocks seeing net outflows, and 13 stocks with outflows exceeding 10 million yuan [2] - The stock with the highest net outflow was Donghua Software, with a net outflow of 1.26 billion yuan, followed by Chuangying Huikang, Weining Health, and Dian Diagnosis [2][3] Group 2 - The top stocks with net outflows in the DRG/DIP concept included Donghua Software (-3.97%), Chuangying Huikang (-6.76%), and Weining Health (-4.60%) [2][3] - Conversely, the stocks with net inflows included Huaping Co., Guoke Hengtai, and Wanda Information, with net inflows of 238.84 million yuan, 166.15 million yuan, and 121.00 million yuan respectively [2]

Group 1: Company Performance and Financials - The company reported a cautious approach to asset impairment testing due to macroeconomic uncertainties, leading to increased expenses and losses despite government subsidies received in the previous year [3][4]. - The company has a robust cash flow situation, with sufficient working capital, and is applying for credit lines from banks to optimize cash assets [3][4]. - The company aims to enhance profitability through increased R&D investment in advanced technologies and high-value products, while also optimizing production processes and supply chain management [3][4]. Group 2: Strategic Planning and Market Position - The company has established a clear three-pronged strategic plan focusing on business, financial, and product innovation goals, leveraging its core competencies in the video conferencing sector [6][12]. - The new management team is committed to developing strategies based on external market conditions and internal capabilities, with a focus on enhancing profitability and shareholder returns [7][12]. - The company is actively evaluating its asset structure and will continue to assess the strategic alignment and investment returns of its assets [4][6]. Group 3: Investor Relations and Communication - The company has implemented a market value management system to improve communication and management practices, aiming to reflect its investment value accurately [4][15]. - The company has conducted an online earnings briefing to engage with investors and address their inquiries regarding performance and future strategies [2][3]. - The company has committed to timely disclosures regarding stock repurchase plans and other significant corporate actions [14][15]. Group 4: Industry Trends and Future Outlook - The company is exploring new market demands and applications for its command and dispatch systems, indicating a proactive approach to market expansion [10][12]. - The company is focusing on the development of AI-driven products in the healthcare sector through its subsidiary, aiming to enhance operational efficiency and user responsiveness [16][19]. - The company is considering investments in low-altitude economy projects and has previously collaborated with DJI in related fields [17][19].

Core Viewpoint - The implementation of the "Pharmaceutical Industry Digital Transformation Implementation Plan (2025-2030)" by seven government departments aims to enhance the digital transformation across the entire pharmaceutical industry chain, focusing on the deep application of artificial intelligence technology and the cultivation of excellent enterprises [1][3]. Group 1: Market Impact - Following the announcement, the pharmaceutical digitalization sector in the A-share market saw a collective rise, with notable increases such as 13.16% for Sichuang Medical [2][1]. - The digital transformation plan is expected to create significant opportunities for the pharmaceutical industry, effectively equipping it with a "digital brain" to enhance efficiency and reduce costs [6][7]. Group 2: Development Goals - The plan outlines two key stages: by 2027, significant progress in digital transformation should be achieved, and by 2030, large-scale pharmaceutical enterprises should have fully realized digital transformation [3][4]. - Specific targets include the development of over 30 digital technology standards and the establishment of more than 100 exemplary application scenarios in the pharmaceutical industry [4][5]. Group 3: Key Tasks - The plan identifies four major tasks: empowering with digital technology, promoting digital transformation, building a digital service system, and enhancing digital regulation [5][6]. Group 4: Market Growth Potential - The digital healthcare market in China is projected to exceed 1.2 trillion yuan by the end of 2024, with a compound annual growth rate of 24.5% [8]. - By 2025, the digital healthcare market is expected to surpass 1.8 trillion yuan, and by 2030, it could reach 2.5 trillion yuan, indicating a significant market opportunity driven by policy, technology, and demand [9]. Group 5: Company Innovations - Companies like Hengrui Medicine and Fosun Pharma are collaborating with AI platforms to enhance the efficiency of innovative drug development [11]. - Other firms, such as WuXi AppTec and Chengdu XianDao, are integrating AI into their research processes to improve precision and efficiency in drug development [10][11].